sanddollar, there is Cardinal as you suggest, but there are many other possibilities in my opinion. CDEX marks another step in developing a global coalition of world class hospitals working together to address major medication delivery issues.
In my opinion, GE Marquette Medical Systems could be interested one fine day.
CDEX's Mr Pouligny was associated with "Marquette Medical" so I checked out GE Marquette Medical Systems- a leading global provider of medical diagnostic equipment
Mr. Pascal Pouligny, Vice President of International Sales and Marketing He has successfully launched new medical products and services into the European, Middle East and Asian markets for startup and major companies, including Cardinal Health, Hospivision, Hill-Rom, and Marquette Medical Systems.
http://www.gehealthcare.com/auen/msabout/msabout.html GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our vision for the future is to enable a new "early health" model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries.
It is reasonable to think that the CDEX/ValiMed Vice President of International Sales and Marketing, having a background directly involving Marquette Medical, and I suspect in the United Kingdom based upon the London Imperial College Healthcare NHS Trust Partnership Cooperation news, might think of sharing this with Marquette Medical, and others...
Improving Medication Safety: Independent 18 Month Study of ValiMed™ Medication Validation System by CDEX Published in American Journal of Health-System Pharmacists ValiMed™ detected five potentially serious medication errors while consistently validating the correct medication solutions during an 18 month study at a major University Hospital.
Pascal Pouligny, CDEX VP of International Sales and Marketing headquartered in Paris, France, demonstrated ValiMed to an enthusiastic international audience. Xavier Guix, Marketing Director at Grifols International stated, “ValiMed has great promise for the international market. By validating the medication itself and not simply the packaging provides a whole new level of patient safety that we are exploring with great interest.” Grifols International, with headquarters in Barcelona, Spain, is a leading, world-wide supplier of medical products and services.
The CDEX Team of Stuart Poteet, Tim Shriver, Jr., Cynthia Sampson, Malcolm Philips, Pascal Pouligny and Tim Shriver, also demonstrated the Meth Scanner to interested representatives including the Governor of Nevada Jim Gibbons and his wife, Dawn Gibbons, and unveiled a new, low-cost Fentanyl Validation System for strengthening procedure to prevent narcotic diversion in medical facilities. In addition, Tim Shriver, CDEX Senior VP of Technical Operations, responded to inquiries from equipment manufacturers about the integrated use of the CDEX technology in medical equipment that distributes controlled substances and equipment that automatically compounds medications. “The continued expansion of the ValiMed Signature Library offers us the opportunity to consider integration of our technology into related medical products,” said Mr. Shriver. “This is an exciting expansion that we looked at three years ago and are now ready to explore aggressively.”
UK's first Academic Health Science Centre incorporating London’s St Mary's and Hammersmith Hospitals, in partnership with Imperial College London to test ValiMed™ in clinical pharmacy settings and engage in new product development.
Tucson, Arizona and London, England – January 23, 2008 – CDEX Inc. (OTCBB: CEXI) follows up on recent announcements regarding international expansion by announcing today a partnership cooperation with the Imperial College Healthcare NHS Trust in London to test ValiMed in the Hammersmith and Charing Cross hospitals and to work together in developing new medication signatures including chemotherapy and cytostatic drugs. The ValiMed Medication Validation System uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. ValiMed compares a medication’s spectroscopic signature to the expected signature from the CDEX Medication Signature Library and returns an easy to understand “validated” or “not validated” result, requiring no user interpretation.
On January 7, 2008, CDEX announced publication of an 18 month independent study of the ValiMed™ Medication Validation System at the C.S. Mott Children's Hospital in the University of Michigan Health System in the American Journal of Health-System Pharmacists. “During the 18 months since [ValiMed] was implemented, five potentially serious medication errors have been detected and avoided,” the report stated. “[ValiMed] consistently validated the correct solution, while dependably detecting as invalid the wrong drug or concentrations that departed substantially from the targeted standard.” The press release from the University of Michigan can be accessed at http://www.ns.umich.edu/htdocs/releases/story.php?id=6255.
“We are delighted to have this opportunity to work in partnership with CDEX. By working in collaboration we will ensure product development is completely aligned with patient need to the mutual benefit of all,” said Professor Ann Jacklin, Chief Pharmacist at Hammersmith & Charing Cross hospitals, Imperial College Healthcare NHS Trust, and Visiting Professor at The School of Pharmacy University of London. In 2000 Ms. Jacklin initiated the formation of the Centre for Medicines Safety and Service Quality, a joint research centre between Hammersmith Hospital and the School of Pharmacy, and has been joint Chair of the centre since this time.
“We are honored that Professor Jacklin and her staff have elected to partner with CDEX in testing the ValiMed technology and developing new applications and signatures that will dramatically increase patient medications safety where it is most needed” said Malcolm Philips, CDEX President and CEO. “This marks another step in developing a global coalition of world class hospitals working together to address major medication delivery issues.”
News 
Market Data 
Discover 
